Recursion OS Approach Impact Pipeline Partners Investors About Careers Recursion OS Approach Impact Pipeline Partners Investors About Careers One of the largest, broadest and deepest pipelines of any technology-enabled drug discovery company. Every program at Recursion is a product of our Recursion OS. With every new discovery, our platform gets smarter, leading to pipeline growth. Our programs target diseases spanning several therapeutic areas where: 1. the cause of the disease is well-defined 2. there is high unmet need, there are no approved therapies, or there are significant shortcomings with existing treatment paradigms Expanded Access Policy Disease Indication Early Discovery Late Discovery Preclinical Phase 1 Phase 2 Commercial Neurofibromatosis Type 2 Cerebral Cavernous Malformation Familial Adenomatous Polyposis GM2 Gangliosidosis Clostridium difficile Colitis Immune checkpoint resistance in STK11 -mutant NSCLC Pulmonary Arterial Hypertension Senolytics Neuroinflammation Oncology (small molecule MYC Inhibitors) Cancer Immunotherapy Target Alpha Cancer Immunotherapy Target Beta Hepatocellular carcinoma Charcot-Marie-Tooth Disease Type 2 Batten Disease 41 Early Discovery Programs Welcome to the era of industrialized drug discovery. Proud founding member of BioHive, the fastest growing life sciences community in the nation Get In Touch 41 S Rio Grande Street Salt Lake City, UT 84101 phone: (385) 269-0203 fax: (801) 821-2872 info@recursion.com Investor Relations Connect LinkedIn Twitter Youtube